Eevia Health Plc ("Eevia" or "The Company") has decided to adjust the planned time for several financial events in 2023.
Eevia has decided for practical reasons to adjust the planned time for several financial events, as follows:
- Interim report Q1 2023 publishing is moved from 15 MAY 2023 to 16 MAY 2023
- The Annual General Meeting is moved from 25 MAY 2023 to 26 JUNE 2023
Hence, the revised immediate financial calendar is now as follows:
- Interim report Q1 2023 - 16 MAY 2023
- The Annual General Meeting - 26 JUNE 2023
- The Interim report Q2 2023 - 23 AUGUST 2023
- The Interim report Q3 2023 - 22 NOVEMBER 2023
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands use the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.